Semi-synthetic mithramycin SA derivatives with improved anticancer activity

Chemical Biology and Drug Design

Volumn 81, Issue 5, 2013, Pages 615-624

  Scott, Daniel ^a   Chen, Jhong Min ^a   Bae, Younsoo ^a   Rohr, Jürgen ^a  

^a University of Kentucky   (United States)

Author keywords

Anticancer; Aureolic acid; Mithramycin; Mithramycin SA; Semi synthesis

Indexed keywords

AGLYCONE; ANTINEOPLASTIC AGENT; CARBON; CARBOXYLIC ACID; DNA; MITHRAMYCIN; MITHRAMYCIN SA DERIVATIVE; MITHRAMYCIN SDK; MITHRAMYCIN SK; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTECHNOLOGICAL PRODUCTION; CANCER CELL; CONTROLLED STUDY; DERIVATIZATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; STREPTOMYCES; STREPTOMYCES ARGILLACEUS;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; PLICAMYCIN;

EID: 84876875228     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12107     Document Type: Article

References (33)

1. Cragg G.M., Newman D.J., Snader K.M. (1997) Natural products in drug discovery and development. J Nat Prod;60:52-60.
2. Newman D.J., Cragg G.M., Snader K.M. (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod;66:1022-1037.
3. Newman D.J., Cragg G.M. (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod;75:311-335.
4. Miller D.M., Polansky D.A., Thomas S.D., Ray R., Campbell V.W., Sanchez J., Koller C.A. (1987) Mithramycin selectively inhibits transcription of G-C containing DNA. Am J Med Sci;294:388-394.
5. Sastry M., Fiala R., Patel D.J. (1995) Solution structure of mithramycin dimers bound to partially overlapping sites on DNA. J Mol Biol;251:674-689.
6. Sastry M., Patel D.J. (1993) Solution structure of the mithramycin dimer-DNA complex. Biochemistry;32:6588-6604.
7. Blume S.W., Snyder R.C., Ray R., Thomas S., Koller C.A., Miller D.M. (1991) Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest;88:1613-1621.
8. Safe S., Abdelrahim M. (2005) Sp transcription factor family and its role in cancer. Eur J Cancer;41:2438-2448.
9. Abdelrahim M., Smith R. III, Burghardt R., Safe S. (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res;64:6740-6749.
10. Black A.R., Black J.D., Azizkhan-Clifford J. (2001) Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol;188:143-160.
11. Kennedy B.J. (1970) Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med;49:494-503.
12. Brown J.H., Kennedy B.J. (1965) Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med;272:111-118.
13. Koller C.A., Miller D.M. (1986) Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med;315:1433-1438.
14. Ryan W.G. (1970) Mithramycin for Paget's disease of bone. N Engl J Med;283:1171.
15. Ryan W.G., Schwartz T.B., Northrop G. (1970) Experiences in the treatment of Paget's disease of bone with mithramycin. JAMA;213:1153-1157.
16. Jin H.-J., Kanthasamy A., Anantharam V., Rana A., Kanthasamy A.G. (2011) Transcriptional regulation of pro-apoptotic protein kinase Cδ: implications for oxidative stress-induced neuronal cell death. J Biol Chem;286:19840-19859.
17. Seznec J., Silkenstedt B., Naumann U. (2011) Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J Neurooncol;101:365-377.
18. Sleiman S.F., Langley B.C., Basso M., Berlin J., Xia L., Payappilly J.B., Kharel M.K. et al. (2011) Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci;31:6858-6870.
19. Gao Y., Jia Z., Kong X., Li Q., Chang D.Z., Wei D., Le X., Suyun H., Huang S., Wang L., Xie K. (2011) Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res;71:5182-5193.
20. Tagashira M., Kitagawa T., Isonishi S., Okamoto A., Ochiai K., Ohtake Y. (2000) Mithramycin represses MDR1 gene expression in vitro, modulating multidrug resistance. Biol Pharm Bull;23:926-929.
21. Tagashira M., Kitagawa T., Nozato N., Isonishi S., Okamoto A., Ochiai K. (2000) Two novel C-glycosides of aureolic acid repress transcription of the MDR1 gene. Chem Pharm Bull (Tokyo);48:575-578.
22. Grohar P.J., Woldemichael G.M., Griffin L.B., Mendoza A., Chen Q.-R., Yeung C., Currier D.G., Davis S., Khanna C., Khan J., McMahon J.B., Helman L.J. (2011) Identification of an inhibitor of the EWS-FLI1 oncogenic transcription Factor by high-throughput screening. J Natl Cancer Inst;103:962-978.
23. Albertini V., Jain A., Vignati S., Napoli S., Rinaldi A., Kwee I. et al. (2006) Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res;34:1721-1734.
24. Remsing L.L., Gonzalez A.M., Nur-e-Alam M., Fernandez-Lozano M.J., Brana A.F., Rix U., Oliveira M.A., Méndez C., Salas J.A., Rohr J. (2003) Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J Am Chem Soc;125:5745-5753.
25. Remsing L.L., Bahadori H.R., Carbone G.M., McGuffie E.M., Catapano C.V., Rohr J. (2003) Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target. Biochemistry;42:8313-8324.
26. Tevyashova A.N., Olsufyeva E.N., Turchin K.F., Balzarini J., Bykov E.E., Dezhenkova L.G., Shtil A.A., Preobrazhenskaya M.N. (2009) Reaction of the antitumor antibiotic olivomycin I with aryl diazonium salts. Synthesis, cytotoxic and antiretroviral potency of 5-aryldiazenyl-6-O-deglycosyl derivatives of olivomycin I. Bioorg Med Chem;17:4961-4967.
27. Tevyashova A.N., Shtil A.A., Olsufyeva E.N., Luzikov Y.N., Reznikova M.I., Dezhenkova L.G., Isakova E.B., Bukhman V.M., Durandin N.A., Vinogradov A.M., Kuzmin V.A., Preobrazhenskaya M.N. (2011) Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics. Bioorg Med Chem;19:7387-7393.
28. Tevyashova A.N., Zbarsky E.N., Balzarini J., Shtil A.A., Dezhenkova L.G., Bukhman V.M., Zbarsky V.B., Preobrazhenskaya M.N. (2009) Modification of the antibiotic olivomycin I at the 2′-keto group of the side chain. Novel derivatives, antitumor and topoisomerase I-poisoning activity. J Antibiot;62:117.
29. Scott D., Rohr J., Bae Y. (2011) Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity. Int J Nanomedicine;6:2757-2767.
30. Mann C.M., Markham J.L. (1998) A new method for determining the minimum inhibitory concentration of essential oils. J Appl Microbiol;84:538-544.
31. Gibson M., Nur-e-Alam M., Lipata F., Oliveira M.A., Rohr J. (2005) Characterization of kinetics and products of the Baeyer-Villiger oxygenase MtmOIV, the key enzyme of the biosynthetic pathway toward the natural product anticancer drug mithramycin from Streptomyces argillaceus. J Am Chem Soc;127:17594-17595.
32. Li Y., Lokitz B.S., Armes S.P., McCormick C.L. (2006) Synthesis of reversible shell cross-linked micelles for controlled release of bioactive agents. Macromolecules;39:2726-2728.
33. Koo A.N., Lee H.J., Kim S.E., Chang J.H., Park C., Kim C., Park J.H., Lee S.C. (2008) Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. Chem Commun;6570-6572.